CAR-T

#Cancer research #Cancer vaccine #CAR-T #Clinical trial #Oncology #Personalised medicine

New DDW Highlights podcast: 29 April 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The leading news story this week has been the launch of a new clinical… Read More

#News

#Cancer research #Cancer vaccine #CAR-T #Clinical trial #Oncology #Personalised medicine

This week in drug discovery (22-26 April) 

News round-up for 22-26 April by DDW Digital Content Editor Diana Spencer. The leading news story this week has been the launch of a new clinical trial in the UK for a melanoma personalised mRNA cancer vaccine, but there have been a number of other interesting developments in… Read More

#News

CAR-T therapy
#CAR-T #European Commission #Janssen #Myeloma #Oncology #Phase III trial

EC expands use of BCMA-targeted CAR-T therapy

The European Commission (EC) has approved a Type II variation for Carvykti (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM). It is approved in patients who have received at least one prior therapy, including an immunomodulatory agent (IMiD) and a proteasome inhibitor… Read More

#News #Regulatory

Cancer cells
#Breast cancer #Cancer research #CAR-T #Cell therapy #Oncology

eBook: Breakthroughs in oncology research and drug discovery

While the age-adjusted overall cancer death rate in the US fell by 33% between 1991 and 2020, cancer remains a significant threat to human health, with more than two million new cases expected to be diagnosed in 2024 and uneven progress across different cancer types1. These… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Financing #Gene therapy

This week in drug discovery (18-22 March) 

News round-up for 18-22 March by DDW Digital Content Editor Diana Spencer. This has been an interesting week for cell and gene therapies, with two landmark FDA approvals, two significant fundraising efforts and potentially ground-breaking study results in glioblastoma. The top stories: ‘Dual-target’… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Financing #In vivo #Investment

$175M financing will support development of in vivo CAR-T therapies

Biotechnology company Capstan Therapeutics has raised $175 million in an oversubscribed Series B financing. The proceeds will be used to advance CPTX2309, Capstan’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan’s tLNP pipeline. CPTX2309 delivers an… Read More

#Business & Investment #News

CAR-T therapy
#Blood cancer #Bristol Myers Squibb #CAR-T #Cell therapy #FDA #Leukaemia #Oncology

FDA approves first CAR-T cell therapy for relapsed CLL or SLL

The US Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It is approved in adult patients who have received at least two… Read More

#News #Regulatory #Trending News

MRI showing glioblastoma
#Brain cancer #CAR-T #Cell therapy #Oncology #University of Pennsylvania

‘Dual-target’ CAR-T cell therapy shrinks brain tumours

Targeting two brain tumour-associated proteins – rather than one – with CAR-T cell therapy has shown promise as a strategy for reducing solid tumour growth in patients with recurrent glioblastoma (GBM). This is according to early results from the first six patients treated in an ongoing… Read More

#Cancer Research #News

T cells attacking cancer
#CAR-T #Elicera Therapeutics #Lung cancer #Oncology #Partnership #Skin cancer #T cell receptor (TCR)

Collaborators investigate novel T-cell receptor therapy

Elicera Therapeutics has entered a Material Transfer Agreement (MTA) with a prominent US cancer centre to evaluate the enhancing effect of the iTANK-technology in a novel T-cell receptor therapy targeting skin cancer and lung cancer. Elicera Therapeutics will make parts of its technology iTANK available to… Read More

#Cancer Research #News

CAR-T therapy
#CAR-T #Cell therapy #CHMP #European Medicines Agency #Myeloma #Oncology

CAR-T therapy recommended for melanoma after first relapse

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a Type II variation for Carvykti (ciltacabtagene autoleucel; cilta-cel) for the earlier treatment of relapsed and refractory multiple myeloma (RRMM). The recommended indication for cilta-cel is for the treatment of… Read More

#News #Regulatory

Cancer cells
#Antibody #Brain cancer #Cancer research #CAR-T #CRISPR #Oncology

2023 cancer research highlights: Drug development at its best

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Figures from the Amercian Cancer Society1 state that “a little over… Read More

#Cancer Research #Exclusive Content

DNA research molecule
#CAR-T #DNA #Epigenomics #Genetic editing #Genomics #Immunology #Oncology #Tune Therapeutic

Moving the needle of CAR-T beyond oncology 

CAR-T Therapies have revolutionised the field of personalised medicine, especially in oncology. DDW’s Megan Thomas speaks with Dr Blythe Sather, Vice President and Head of Research at Tune Therapeutics, about how genetic tuning will transform the reach for CAR-T therapies, the different diseases that can benefit, and the disruptive technology making… Read More

#Cancer Research #Exclusive Content

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Solid tumours

New DDW Highlights podcast: 26 February 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In a breakthrough for advanced therapies, this week saw the FDA approve the first… Read More

#News

Cells under a microscope
#bit bio #CAR-T #Cell therapy #Interview #iPSC #Stem cells

Scaling up: The need for human cells to give better access to cell therapies

Reece Armstrong speaks to Kathryn Golden, SVP Technical Operations and Manufacturing, bit.bio, about novel technologies, and methods to manufacture human cells for therapies so more patients can access these treatments. Cell therapies have emerged as transformative and potentially curative treatments across a range of disease areas. These therapies, which utilise… Read More

#Exclusive Content

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Solid tumours

This week in drug discovery (19-23 February) 

News round-up for 19-23 February by DDW Digital Content Editor Diana Spencer. In a breakthrough for advanced therapies, this week saw the FDA approve the first ever cell therapy for solid tumour cancers, but there were other significant developments in the cell and gene therapy space. The… Read More

#News

#Astellas Pharma #CAR-T #Cell therapy #Collaboration #Immuno-oncology #In vivo #Kelonia Therapeutics #Xyphos Biosciences

Companies agree $800m deal for in vivo CAR-T cell therapy

Astellas-owned Xyphos Biosciences and Kelonia Therapeutics have entered into a research collaboration and license agreement to develop novel immuno-oncology therapeutics. Under the terms of the agreement, the companies plan to combine Kelonia’s iGPS with Xyphos’ ACCEL technology to develop in vivo CAR-T cell therapies targeting up to two programmes. Kevin… Read More

#Business & Investment #News #Trending News